Compare Remitly Global Inc (RELY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs TG Therapeutics Inc — how do they compare? Remitly Global Inc trades at $24.17 (market cap $4.98B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Remitly Global Inc is more actively traded (3,501,150 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and TG Therapeutics Inc for 16 Days on average.
| RELY | TGTX | |
|---|---|---|
Market Cap | $4.98B | $8.16B |
Volume | 3,501,150 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $26.92 | $59.06 |
52-Week Low | $12.20 | $26.94 |
Typical Hold Time | 53 Days | 16 Days |
Enterprise Value | $4.34B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.675, up 3.25% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats. Revenue surged to $1.64 billion in 2025, with net income turning positive at $67.93 million, reflecting a significant improvement in profitability. Recent news highlights partnerships, such as with Etsy, and strong analyst consensus favoring the stock.
The outlook for RELY is positive, driven by robust revenue growth, expanding margins, and a favorable analyst consensus with a $30.50 price target. Key risks include competitive pressures in fintech and reliance on sustained customer acquisition, but institutional interest and insider holdings suggest confidence in long-term value.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
